Skip to main content

Advertisement

Table 2 Ten-years disease/mortality, children ≤59 months, multiple PCV13 catch-up scenarios, assuming no acceleration in indirect effects

From: Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

  PCV13 with no catch-up Catch-up 39% Catch-up 87% Cases prevented due to catch-up (39%) Additional cases potentially prevented with increased catch-upa
IPD 22,261 21,048 19,637 1,176 1,448
Hospitalized Pneumonia 940,580 927,831 912,141 12,749 15,690
Non-hospitalized Pneumonia 14,037,214 13,994,317 13,941,520 42,897 52,797
AOM 144,731,659 144,194,812 143,534,078 536,847 660,735
Deaths 3,141 3,116 3,084 26 32
  1. AOM: acute otitis media; IPD: invasive pneumococcal disease; PCV13: 13-valent pneumococcal conjugate vaccine.
  2. aFrom 39% to 87%.